Cancer Clinical Trial
Official title:
The Use of Complementary Medicine in Palliative/Supportive Care Centres in Lyon, France
| NCT number | NCT03260946 |
| Other study ID # | 69HCL17_0217 |
| Secondary ID | |
| Status | Completed |
| Phase | |
| First received | |
| Last updated | |
| Start date | July 11, 2017 |
| Est. completion date | May 3, 2018 |
| Verified date | August 2017 |
| Source | Hospices Civils de Lyon |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Observational |
Palliative care centres in Lyon, France as well as the disclosure of Complementary and
Alternative Medicine and conventional healthcare use to conventional and Complementary and
Alternative Medicine practitioners respectively.
These aims will be achieved through the following objectives:
1. Describe the prevalence of Complementary and Alternative Medicine practitioner and
product use in the outpatient population of palliative care centres in Lyon, France
2. Describe the characteristics of Complementary and Alternative Medicine users the
outpatient population of palliative care centres in Lyon, France
3. Estimate the Complementary and Alternative Medicine expenditure of the outpatient
population of palliative care centres in Lyon, France
4. Describe the rates of disclosure of both Complementary and Alternative Medicine and
conventional health care to health professionals by the outpatient population of
palliative care centres in Lyon, France
5. Describe the reasons for disclosure or non-disclosure of both Complementary and
Alternative Medicine and conventional health care to health professionals by the
outpatient population of palliative care centres in Lyon, France
| Status | Completed |
| Enrollment | 120 |
| Est. completion date | May 3, 2018 |
| Est. primary completion date | May 3, 2018 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility |
Inclusion Criteria: 1. Patients accessing care from a palliative/supportive care centre in Lyon, France 2. Can read and understand French 3. Has been diagnosed with cancer Exclusion Criteria: 1. The primary health condition for which they are attending the centre is not cancer 2. They are not able to read and understand French |
| Country | Name | City | State |
|---|---|---|---|
| France | Service E.M.S.P. Groupement Hospitalier Nord - Hôpital de la Croix-Rousse | Lyon | |
| France | USP de Charmettes - Croix rouge française | Lyon | |
| France | Centre de Soins Palliatifs Lyon-Sud Pavillon 1K - Centre Hospitalier Lyon-Sud | Pierre-Bénite |
| Lead Sponsor | Collaborator |
|---|---|
| Hospices Civils de Lyon |
France,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Complementary medicine use | The prevalence of complementary medicine use. Data collected using a questionnaire. | 15 minutes |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05346796 -
Survivorship Plan HEalth REcord (SPHERE) Implementation Trial
|
N/A | |
| Recruiting |
NCT05094804 -
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
| Completed |
NCT04867850 -
Effect of Behavioral Nudges on Serious Illness Conversation Documentation
|
N/A | |
| Enrolling by invitation |
NCT04086251 -
Remote Electronic Patient Monitoring in Oncology Patients
|
N/A | |
| Completed |
NCT01285037 -
A Study of LY2801653 in Advanced Cancer
|
Phase 1 | |
| Completed |
NCT00680992 -
Study of Denosumab in Subjects With Giant Cell Tumor of Bone
|
Phase 2 | |
| Completed |
NCT00062842 -
Study of Irinotecan on a Weekly Schedule in Children
|
Phase 1 | |
| Active, not recruiting |
NCT04548063 -
Consent Forms in Cancer Research: Examining the Effect of Length on Readability
|
N/A | |
| Completed |
NCT04337203 -
Shared Healthcare Actions and Reflections Electronic Systems in Survivorship
|
N/A | |
| Recruiting |
NCT04349293 -
Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways
|
N/A | |
| Terminated |
NCT02866851 -
Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy
|
N/A | |
| Active, not recruiting |
NCT05304988 -
Development and Validation of the EFT for Adolescents With Cancer
|
||
| Completed |
NCT00340522 -
Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
|
||
| Recruiting |
NCT04843891 -
Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis.
|
Phase 1 | |
| Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
| Completed |
NCT03109041 -
Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source
|
Phase 1 | |
| Completed |
NCT03167372 -
Pilot Comparison of N-of-1 Trials of Light Therapy
|
N/A | |
| Terminated |
NCT01441115 -
ECI301 and Radiation for Advanced or Metastatic Cancer
|
Phase 1 | |
| Recruiting |
NCT06206785 -
Resting Energy Expenditure in Palliative Cancer Patients
|
||
| Recruiting |
NCT05318196 -
Molecular Prediction of Development, Progression or Complications of Kidney, Immune or Transplantation-related Diseases
|